Articles: nausea.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Nausea and vomiting in day-case dental anaesthesia. The use of low-dose droperidol.
The anti-emetic effects of low-dose droperidol (1.25 mg), ultra-low-dose droperidol (0.25 mg) and a placebo were compared in patients admitted for day-case dental anaesthesia. Ultra-low-dose droperidol produced a significant decrease in the subjective feeling of nausea without delaying recovery or discharge from the hospital (p less than 0.05). Low-dose droperidol did not significantly reduce nausea (p greater than 0.05) and prolonged the recovery time (p less than 0.05).
-
Review Comparative Study
Psychological parameters of chemotherapy-induced conditioned nausea and vomiting: a review.
-
Ann R Coll Surg Engl · Sep 1984
Randomized Controlled Trial Comparative Study Clinical TrialEvaluation of anti-emetics in association with intrathecal diamorphine.
Intrathecal diamorphine is associated with a high incidence of emetic symptoms. Six anti-emetic drugs representing various chemical groups were given in random order to patients undergoing total hip replacement and who had received intrathecal diamorphine 0.5-1.0 mg. The phenothiazines, perphenazine and prochlorperazine, were more effective than the others. It is suggested that this might be a useful model for the evaluation of new anti-emetics.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
We conducted a randomized, double-blind, crossover study comparing the antiemetic efficacy of dexamethasone and prochlorperazine in 42 patients with cancer who were receiving outpatient chemotherapy, mainly without cisplatin. Patients experienced significantly less nausea and vomiting with dexamethasone than with prochlorperazine (P less than 0.02 and less than 0.03, respectively). Twenty-five patients experienced no nausea with dexamethasone, as compared with 14 patients taking prochlorperazine (P less than 0.001). ⋯ Somnolence was the most frequent side effect, occurring in 60 per cent of patients receiving prochlorperazine and in 12 per cent of those receiving dexamethasone (P less than 0.001). Patients also experienced less suppression of appetite while receiving dexamethasone (P less than 0.02). We conclude that dexamethasone is an effective and safe antiemetic in patients receiving cancer chemotherapy without cisplatin.
-
Given the diversity of assessment methodologies in previous studies, and given the increasing attention being shown in studies in which nausea and vomiting are used as outcome measures, it is reasonable to expect that there are more questions on the assessment of nausea and emesis than there are answers. There is little consensus on the efficacy of various approaches used to help control chemotherapy-induced nausea and emesis. There is also little consensus on the appropriate assessment techniques for their measurement. ⋯ It is also important to note that their frequency, severity, and duration are separable phenomena. A complete assessment of nausea and vomiting responses should include separate measures of frequency, severity, and duration. Anticipatory nausea and vomiting are clinical phenomena that appear to occur with a reasonable enough frequency so that their measurement would be important in clinical studies.(ABSTRACT TRUNCATED AT 400 WORDS)